ACM
CSTL icon

Altium Capital Management’s Castle Biosciences CSTL Stock Holding History

Altium Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-60,000
Closed -$1.56M – 105
2022
Q3 		$1.56M Buy
+60,000
New +$1.68M 0.57% 69
2021
Q4 		– Sell
-72,500
Closed -$4.82M – 143
2021
Q3 		$4.82M Buy
72,500
+3,500
+5% +$246K 1.26% 33
2021
Q2 		$5.06M Buy
69,000
+41,635
+152% +$2.75M 1.17% 27
2021
Q1 		$1.87M Sell
27,365
-34,626
-56% -$2.6M 0.52% 84
2020
Q4 		$4.16M Buy
+61,991
New +$3.36M 1.55% 20

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Altium Capital Management's CSTL Position: Q4 2022 in Review

Altium Capital Management sold out of Castle Biosciences (CSTL) in Q4 2022, closing a stake of 60,000 shares — an estimated $1.56M sold.

Altium Capital Management first reported a position in CSTL in Q4 2020 and held it in 5 quarters. The position peaked at $5.06M in Q2 2021. 153 funds tracked by Wall St. Rank hold CSTL as of Q4 2022.

  • Altium Capital Management reported no remaining Castle Biosciences position as of Q4 2022 after selling out during the quarter.
  • Altium Capital Management sold 60,000 Castle Biosciences shares in Q4 2022, an estimated $1.56M.
  • Altium Capital Management first reported a position in Castle Biosciences in Q4 2020 and held it in 5 quarters.
  • Altium Capital Management's Castle Biosciences position peaked at $5.06M in Q2 2021.
  • 153 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2022.

Based on Altium Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.